Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Neuralgia Treatment Market

ID: MRFR/HC/22878-HCR
128 Pages
Satyendra Maurya
Last Updated: April 24, 2026

Neuralgia Treatment Market Research Report By Drug Type (Anticonvulsants, Antidepressants, Opioids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Other), By Route of Administration (Oral, Intravenous, Transdermal, Other), By Severity of Neuralgia (Mild, Moderate, Severe), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Neuralgia Treatment Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Drug Type (USD Billion) | |
      1. 4.1.1 Anticonvulsants | |
      2. 4.1.2 Antidepressants | |
      3. 4.1.3 Opioids | |
      4. 4.1.4 Non-Steroidal Anti-Inflammatory Drugs | |
      5. 4.1.5 Other |
    2. 4.2 Healthcare, BY Route of Administration (USD Billion) | |
      1. 4.2.1 Oral | |
      2. 4.2.2 Intravenous | |
      3. 4.2.3 Transdermal | |
      4. 4.2.4 Other |
    3. 4.3 Healthcare, BY Severity of Neuralgia (USD Billion) | |
      1. 4.3.1 Mild | |
      2. 4.3.2 Moderate | |
      3. 4.3.3 Severe |
    4. 4.4 Healthcare, BY Distribution Channel (USD Billion) | |
      1. 4.4.1 Hospital Pharmacies | |
      2. 4.4.2 Retail Pharmacies | |
      3. 4.4.3 Online Pharmacies | |
      4. 4.4.4 Other |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Pfizer Inc (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Johnson & Johnson (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bristol-Myers Squibb Company (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 AstraZeneca PLC (GB) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Teva Pharmaceutical Industries Ltd (IL) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Novartis AG (CH) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Eli Lilly and Company (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 AbbVie Inc (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 GSK (GB) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DRUG TYPE |
    7. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    8. 6.5 US MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    9. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    10. 6.7 CANADA MARKET ANALYSIS BY DRUG TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    12. 6.9 CANADA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    13. 6.10 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY DRUG TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    17. 6.14 GERMANY MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    18. 6.15 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    19. 6.16 UK MARKET ANALYSIS BY DRUG TYPE |
    20. 6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    21. 6.18 UK MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    22. 6.19 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    23. 6.20 FRANCE MARKET ANALYSIS BY DRUG TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    25. 6.22 FRANCE MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    26. 6.23 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    27. 6.24 RUSSIA MARKET ANALYSIS BY DRUG TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    29. 6.26 RUSSIA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    30. 6.27 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    31. 6.28 ITALY MARKET ANALYSIS BY DRUG TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    33. 6.30 ITALY MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    34. 6.31 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    35. 6.32 SPAIN MARKET ANALYSIS BY DRUG TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    37. 6.34 SPAIN MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    38. 6.35 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY DRUG TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    46. 6.43 CHINA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    47. 6.44 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    48. 6.45 INDIA MARKET ANALYSIS BY DRUG TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    50. 6.47 INDIA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    51. 6.48 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    52. 6.49 JAPAN MARKET ANALYSIS BY DRUG TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    54. 6.51 JAPAN MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    55. 6.52 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    64. 6.61 THAILAND MARKET ANALYSIS BY DRUG TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    66. 6.63 THAILAND MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    67. 6.64 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    68. 6.65 INDONESIA MARKET ANALYSIS BY DRUG TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    70. 6.67 INDONESIA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    71. 6.68 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY DRUG TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    79. 6.76 BRAZIL MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    80. 6.77 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    81. 6.78 MEXICO MARKET ANALYSIS BY DRUG TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    83. 6.80 MEXICO MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    84. 6.81 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY SEVERITY OF NEURALGIA |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY SEVERITY OF NEURALGIA, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY SEVERITY OF NEURALGIA, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DRUG TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY SEVERITY OF NEURALGIA, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Drug Type (USD Billion, 2025-2035)

  • Anticonvulsants
  • Antidepressants
  • Opioids
  • Non-Steroidal Anti-Inflammatory Drugs
  • Other

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Intravenous
  • Transdermal
  • Other

Healthcare By Severity of Neuralgia (USD Billion, 2025-2035)

  • Mild
  • Moderate
  • Severe

Healthcare By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions